344 related articles for article (PubMed ID: 30017537)
1. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
2. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
3. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs involved in the HMGA2 deregulation and its co-occurrence with MED12 mutation in uterine leiomyoma.
Mello JBH; Barros-Filho MC; Abreu FB; Cirilo PDR; Domingues MAC; Pontes A; Rogatto SR
Mol Hum Reprod; 2018 Nov; 24(11):556-563. PubMed ID: 30376129
[TBL] [Abstract][Full Text] [Related]
5. Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities.
Asano R; Asai-Sato M; Matsukuma S; Mizushima T; Taguri M; Yoshihara M; Inada M; Fukui A; Suzuki Y; Miyagi Y; Miyagi E
Fertil Steril; 2019 Jan; 111(1):178-185. PubMed ID: 30554729
[TBL] [Abstract][Full Text] [Related]
6. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease.
Klemke M; Meyer A; Nezhad MH; Bartnitzke S; Drieschner N; Frantzen C; Schmidt EH; Belge G; Bullerdiek J
Genes Chromosomes Cancer; 2009 Feb; 48(2):171-8. PubMed ID: 18980243
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.
Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ
Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations in exon 2 of the MED12 gene are involved in IGF-2 overexpression in uterine leiomyoma.
Di Tommaso S; Tinelli A; Malvasi A; Massari S
Mol Hum Reprod; 2014 Oct; 20(10):1009-15. PubMed ID: 25015674
[TBL] [Abstract][Full Text] [Related]
11. 3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.
Jokinen V; Mehine M; Reinikka S; Khamaiseh S; Ahvenainen T; Äyräväinen A; Härkki P; Bützow R; Pasanen A; Vahteristo P
Genes Chromosomes Cancer; 2023 Jan; 62(1):27-38. PubMed ID: 35822448
[TBL] [Abstract][Full Text] [Related]
12. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
13. Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.
Wu X; Serna VA; Thomas J; Qiang W; Blumenfeld ML; Kurita T
Cancer Res; 2017 Dec; 77(24):6891-6901. PubMed ID: 29055020
[TBL] [Abstract][Full Text] [Related]
14. HMGA proteins regulate the expression of FGF2 in uterine fibroids.
Helmke BM; Markowski DN; Müller MH; Sommer A; Müller J; Möller C; Bullerdiek J
Mol Hum Reprod; 2011 Feb; 17(2):135-42. PubMed ID: 20926602
[TBL] [Abstract][Full Text] [Related]
15. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
16. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
17. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Je EM; Kim MR; Min KO; Yoo NJ; Lee SH
Int J Cancer; 2012 Sep; 131(6):E1044-7. PubMed ID: 22532225
[TBL] [Abstract][Full Text] [Related]
19. Cell cultures in uterine leiomyomas: rapid disappearance of cells carrying MED12 mutations.
Nadine Markowski D; Tadayyon M; Bartnitzke S; Belge G; Maria Helmke B; Bullerdiek J
Genes Chromosomes Cancer; 2014 Apr; 53(4):317-23. PubMed ID: 24446130
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
